Neoplasms
This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.
BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
You are restricted to use this feature as your profile is incomplete. Please complete your profile and provide all required information to activate your account. If you have any questions, please contact us.
Your account is under review for activation. You'll receive a confirmation email as soon as your account is activated. If you have any questions, please contact us.
You are not currently logged in. Please log in to your account, and then try again. If you are not registered yet, click here to sign up.